Experienced in High Potassium Level

Ilkka M. Kantola

Turku, FI 
Experienced in High Potassium Level
Turku, FI 
OverviewLocationsClinical Research

Overview

Ilkka Kantola practices in Turku, Finland. Kantola is rated as an Experienced expert by MediFind in the treatment of High Potassium Level. Their top areas of expertise are Fabry Disease, Hypertension, Type 2 Diabetes (T2D), and Maturity Onset Diabetes of the Young.

Their clinical research consists of co-authoring 57 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of High Potassium Level.

Locations

Turku, Finland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
Enrollment Status: Terminated
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drug: Replagal
Study Phase: Phase 3
A Multi-Center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients With Fabry Disease
A Multi-Center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients With Fabry Disease
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Biological
Study Phase: Phase 3
An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal® Enzyme Replacement Therapy Administered to Adult Patients With Fabry Disease
An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal® Enzyme Replacement Therapy Administered to Adult Patients With Fabry Disease
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Biological
Study Phase: Phase 3
View 2 Less Clinical Trials

57 Total Publications

Genetics, cardiac phenotype and cardiovascular outcomes in Fabry disease patients in Finland.
Genetics, cardiac phenotype and cardiovascular outcomes in Fabry disease patients in Finland.
Journal: ESC heart failure
Published: January 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kantola's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile